Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
| Autor: | Craig S Conoscenti, Joao A. de Andrade, Ipf-Pro Registry investigators, Linda Davidson-Ray, Shaun Bender, Scott M. Palmer, Yanni Fan, Patricia A. Cowper |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Critical Care and Intensive Care Medicine 03 medical and health sciences Idiopathic pulmonary fibrosis FEV1/FVC ratio 0302 clinical medicine DLCO Fibrosis Humans Medicine Prospective Studies Registries 030212 general & internal medicine Hospital Costs Aged business.industry Hospital based Patient Acceptance of Health Care medicine.disease Idiopathic Pulmonary Fibrosis United States Icu admission Hospitalization 030228 respiratory system Emergency medicine Resource use Female Observational study Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | Chest. 157:1522-1530 |
| ISSN: | 0012-3692 |
| DOI: | 10.1016/j.chest.2019.12.041 |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a rare and serious condition that is associated with high health-care resource use. The goal of this study was to estimate hospital-related resource use and costs by using a national, prospective registry of patients who were diagnosed with IPF or who had their diagnosis confirmed at the enrolling center in the past 6 months in the United States.Participants enrolled between June 5, 2014, and April 12, 2016, in the ongoing Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry were included (N = 300). Time to first hospitalization was analyzed by using Kaplan-Meier methods. Annualized costs were estimated for hospitalizations, ICU admissions, and ED visits.At enrollment, most participants were male (75%), white (95%), commercially insured (64%), smokers (68%), had an FVC between 50% and 80% predicted (66%), and received antifibrotic drugs (55%). During the first 12 months of follow-up, participants averaged 0.11 ED visit, 0.42 hospitalization, 0.08 ICU admission, 2.18 hospital days, and 0.45 ICU day. Probability of hospitalization was 18% and 30% at 6 and 12 months, respectively, and was highest for those with FVC 50% predicted/diffusing lung capacity for carbon monoxide 30% predicted. Mean annual costs (95% CI) for ICU admission and inpatient care were $10,098 ($4,732-$16,662) and $13,975 ($8,482-$20,918), respectively, per patient.IPF is associated with a substantial economic burden incurred by patients requiring hospital care. Future research in IPF should focus on improving clinical outcomes while reducing cost of care in hospitals.ClinicalTrials.gov; No.: NCT01915511; URL: www.clinicaltrials.gov. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|